What Happened?
Winston-Salem, NC-based ProKidney Appointed Prakash Narayan as Vice President, Bioprocess Research and Development
About the Company
ProKidney, a pioneer in the treatment of chronic kidney disease (CKD) through innovations in cellular therapy, was founded in 2015 after a decade of research. ProKidney`s lead product candidate, REACT® (Renal Autologous Cell Therapy), is a first-of-its-kind, patented disease-modifying autologous cellular therapy with the potential to not only slow and stabilize the progression of CKD, but in some cases drive meaningful improvement in kidney function. REACT® has received Regenerative Medicine Advanced Therapy (RMAT) designation, as well as FDA and EMA guidance, supporting an immediate start to a global registrational program, which launched in the United States on schedule in January 2022. On January 18, 2022, ProKidney announced that it would become a publicly traded company via a business combination with Social Capital Suvretta Holdings Corp. III
About the Person
Prakash Narayan is Vice President, Bioprocess Research and Development at ProKidney. Previously, Prakash held various senior HR leadership roles in the industry.
Info Source
News
Short Profile